Drug Profile
NUC B1000
Alternative Names: HepXLatest Information Update: 20 Jan 2011
Price :
$50
*
At a glance
- Originator Nucleonics
- Class Antivirals
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 05 Nov 2007 Phase-I clinical trials in Hepatitis B treatment in Eastern Europe (IV)
- 05 Nov 2007 Phase-I clinical trials in Hepatitis B treatment in USA (IV)
- 03 May 2007 Nucleonics receives clearance from the US FDA to begin a phase I clinical trial in the US and Europe for chronic hepatitis B infections